New Board Members
by Eric Gray, Vice Chair

The mission of the Hemophilia Alliance is to work “to ensure member Hemophilia Treatment Centers have the expertise, resources and public support to sustain their integrated clinical and pharmacy services for individuals with bleeding and clotting disorders”. Per the Hemophilia Alliance by-laws, “The Board of Directors should, to the extent feasible, include members representative of the eight (8) regional networks of hemophilia treatment centers, types of programs, expertise, and experience.”

We want to sincerely thank all applicants for their interest in serving on the board. We thoughtfully reviewed and considered all applicants in the context of the Mission and by-laws, seeking to most broadly represent our membership as well as diversify our expertise and insight to most strategically address challenges to further our mission.

We are pleased to announce Dean Hindenlang and Leigh Carpenter have been elected to serve on the Board, with their terms beginning June 2022. Dean is the Director of Public Policy, Advocacy and Community Impact with Cascade Hemophilia Consortium in Ann Arbor, Michigan. Prior to becoming employed, Dean was the President of the Board of Directors. He has a Ph.D. in Public Policy and Administration and has held multiple roles in non-profit, University and government organizations. Leigh is the Vice President of Pharmacy Operations for Hemophilia of Georgia in Sandy Springs, Georgia. Leigh has been with HoG for over 20 years and assisted in the growth of their 340B program, expansion of contract pharmacy relationships and obtaining dual specialty pharmacy accreditation status. They are both excited to advocate for patients both on a local and national level, support member HTC’s and serve on the Board.

Again, we can’t thank enough the individuals who applied to serve on the board. We may be reaching out to you to assist in serving the Alliance in other ways.